Diabetes, Vol 37, Issue 11 1531-1541, Copyright © 1988 by American Diabetes Association
Stimulation of glucose production through hormone secretion and other mechanisms during insulin-induced hypoglycemia
RT Frizzell, GK Hendrick, LL Brown, DB Lacy, EP Donahue, RK Carr, PE Williams, AF Parlow, RW Stevenson and AD Cherrington
Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN 37232.
To assess the role of counterregulatory hormones per se in the response to
continuous insulin infusion, overnight-fasted dogs were given 5
mU.kg-1.min-1 insulin intraportally either alone (INS, n = 5), with glucose
to maintain euglycemia (INS + GLU, n = 5), or with glucose and hormone
replacement [i.e., glucagon, epinephrine, norepinephrine, and cortisol
infusions (INS + GLU + HR, n = 6)]. The increases in counterregulatory
hormones that occurred during insulin-induced hypoglycemia were simulated
in the latter group. In this way, it was possible to separate the effects
of hypoglycemia per se from those due to the associated counterregulatory
hormone response. Glycogenolysis and gluconeogenesis were measured with a
combination of tracer ([ 3-3H]glucose and [U-14C]alanine) and hepatic
arteriovenous (AV) difference techniques during a 40-min control and a
180-min experimental period. Insulin levels increased similarly in all
groups (to congruent to 250 microU/ml), whereas plasma glucose levels
decreased in INS (115 +/- 3 to 41 +/- 3 mg/dl; P less than .05) and rose
slightly in both INS + GLU (108 +/- 2 to 115 +/- 4 mg/dl; P less than .05)
and INS + GLU + HR (111 +/- 3 to 120 +/- 3 mg/dl; P less than .05) due to
glucose infusion. Glucagon, epinephrine, norepinephrine, and cortisol were
replaced in INS + GLU + HR so that the increments in their levels were 102
+/- 6, 106 +/- 14, 117 +/- 9, and 124 +/- 37%, respectively, of their
increments in INS. At no time was there a significant difference between
the hormone levels in INS and INS + GLU + HR. The rise in the
counterregulatory hormones per se accounted for only half (53 +/- 9% by the
AV difference method and 54 +/- 10% by tracer method) of the glucose
production associated with hypoglycemia resulting from insulin infusion.
The rate and efficiency of alanine conversion to glucose in the
hormone-replacement studies were only 29 +/- 10 and 50 +/- 27% of what
occurred during hypoglycemia induced by insulin infusion. In conclusion,
the counterregulatory hormones alone (i.e., without accompanying
hypoglycemia) can account for only 50% of the glucose production that is
present during insulin-induced hypoglycemia. The remaining 50%, therefore,
must result from effects of hypoglycemia other than its ability to trigger
hormone release.